Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

The Orphan Drug Fact File [2020]

Product Code:
596201564
Publication Date:
November 2020
Format:
PDF + XLSX
Price:
$2,095

Everything you need to know about current activity and new opportunities in orphan drugs

  • Over 7,600 orphan drug designations covered in a flexible data file
  • A detailed report providing 12 in-depth therapy-based orphan drug activity profiles and an assessment of orphan drug market dynamics

With year-on-year growth outstripping that of the pharmaceutical market as a whole, sales of orphan drugs are forecast to rise to $217 billion by 2024 and could account for 18% of total prescription drug sales. The orphan drugs sector presents investors, big pharma and biotech companies with significant commercial benefits. With major brands such as Merck's Keytruda, Bristol Myers Squibb's Revlimid and Opdivo demonstrating the potential, stakeholders must carefully scan the future orphan drug development landscape to identify the next opportunities.

Fully updated and expanded, The Orphan Drug Fact File 2020 is a comprehensive, independent analysis that provides a complete assessment of orphan drug research activity.

This report will help you to

  • Build a deep understanding of orphan drug market dynamics and performance
  • Identify niche orphan disease opportunities and potential investment areas
  • Profile potential acquisition or collaboration opportunities
  • Plan orphan drug clinical research in the knowledge of other programs
  • Monitor trends in FDA and EMA orphan drug designation
  • Track the activity of key competitors and specific disease areas

Answering key questions such as...

  • Anti-infectives: There are 177 companies developing 353 named anti-infective molecules—what are they working on?
  • Cardiovascular disorders: What are the leading target conditions in the cardiovascular area?
  • Hematology: How many molecules received orphan drug designation in the US and EU in 2019?
  • Immunology: Systemic sclerosis is receiving a lot of attention—which companies are involved and what is the status of their research?
  • Inflammatory disorders: There are 38 trials in Phase III—what are they for?
    • Musculoskeletal disorders: Beyond Duchenne muscular dystrophy and spinal muscular atrophy, what are the rare conditions being targeted?
  • Neuroscience: 21 orphan drugs are in Phase III trials—what are they and who are the developers?
  • Oncology: Of the 2,909 orphan drug molecules how many are targeting pancreatic cancer, multiple myeloma and hepatocellular carcinoma?

This unrivalled resource provides

  • A comprehensive overview of the market dynamics, legal definition and US/EU incentives for orphan drugs
  • An analysis of orphan drug designation trends in the US and EU
  • Extensive reviews by therapeutic area identifying FDA and EMA designation status
  • Analysis of the orphan diseases and conditions that are attracting developer interest and research effort
  • At-a-glance overview of companies' orphan drug portfolios

This unrivalled resource provides

  • A comprehensive overview of the market dynamics, legal definition and US/EU incentives for orphan drugs
  • An analysis of orphan drug designation trends in the US and EU
  • Extensive reviews by therapeutic area identifying FDA and EMA designation status
  • Analysis of the orphan diseases and conditions that are attracting developer interest and research effort
  • At-a-glance overview of companies' orphan drug portfolios

Focus on key therapy areas

  • Anti-infectives
  • Cardiovascular disorders
  • Dermatology
  • Haematology (blood and blood clotting)
  • Immunology
  • Inflammatory disorders
  • Metabolic disorders
  • Musculoskeletal disorders
  • Neuroscience
  • Oncology
  • Ophthalmology
  • Respiratory disorders

Deliverables: Includes PDF Report and Excel Data File

The Orphan Drug Fact File 2020 is delivered as:

  • PDF Analysis Report: Organized by therapy area, and with easy-to-read charts, tables and figures, the report identifies market trends, the designation status, conditions being targeted in 12 key therapy areas, the leading developers and the current/planned clinical trial landscape.
  • Excel Data: This powerful resource allows you to really drill down into more than 7,600 orphan drug molecules for key insights. All the data in the report is included in a well-structured Excel spreadsheet for your further analysis or incorporation into internal data analytics platforms.

Why buy This FirstWord ChartViews report?

  • Relevant: Organized so you can go straight to the information that's most important to you
  • Easy to navigate: Packed with charts and data tables to help you see the full picture
  • Extensive: Over 7,600 drugs with orphan drug designation in US and/or EU
  • Convenient: We've done the hard research work—so you don't have to
  • Comprehensive: Draws together key data from organizations such as the EMA, the FDA, the US National Organization for Rare Diseases, Orpha.net, pharma company pipelines, ClinicalTrials.gov, patient support groups and the World Health Organization



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved